Neda Rasouli
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 38 | 2024 | 1208 | 4.370 |
Why?
| | Diabetes Mellitus, Type 2 | 41 | 2025 | 2531 | 4.120 |
Why?
| | Metformin | 20 | 2025 | 331 | 2.950 |
Why?
| | Thiazolidinediones | 20 | 2014 | 137 | 2.370 |
Why?
| | Prediabetic State | 10 | 2024 | 253 | 2.310 |
Why?
| | Adipose Tissue | 24 | 2016 | 635 | 2.060 |
Why?
| | Hypoglycemic Agents | 34 | 2025 | 1291 | 2.060 |
Why?
| | Insulin-Secreting Cells | 8 | 2025 | 377 | 1.990 |
Why?
| | Sulfonylurea Compounds | 6 | 2025 | 48 | 1.430 |
Why?
| | Glucagon-Like Peptides | 3 | 2025 | 58 | 1.320 |
Why?
| | Blood Glucose | 26 | 2025 | 2186 | 1.300 |
Why?
| | Vitamin D Deficiency | 2 | 2022 | 186 | 1.300 |
Why?
| | Obesity | 24 | 2019 | 2992 | 1.240 |
Why?
| | Cholecalciferol | 4 | 2022 | 60 | 1.190 |
Why?
| | Insulin | 23 | 2025 | 2409 | 1.070 |
Why?
| | Peripheral Arterial Disease | 4 | 2025 | 475 | 1.030 |
Why?
| | Cholesterol, HDL | 2 | 2018 | 203 | 1.000 |
Why?
| | Triglycerides | 3 | 2018 | 524 | 0.910 |
Why?
| | Fenofibrate | 2 | 2016 | 28 | 0.890 |
Why?
| | Glucose Tolerance Test | 15 | 2025 | 366 | 0.860 |
Why?
| | Insulin Glargine | 9 | 2025 | 84 | 0.820 |
Why?
| | Muscle, Skeletal | 11 | 2016 | 1724 | 0.760 |
Why?
| | Metabolic Syndrome | 3 | 2018 | 354 | 0.710 |
Why?
| | Receptors, Ghrelin | 1 | 2020 | 8 | 0.690 |
Why?
| | Gastroparesis | 1 | 2020 | 9 | 0.690 |
Why?
| | PPAR gamma | 8 | 2014 | 182 | 0.680 |
Why?
| | Lipid Metabolism | 5 | 2016 | 518 | 0.650 |
Why?
| | Middle Aged | 53 | 2025 | 33479 | 0.650 |
Why?
| | Diabetic Neuropathies | 1 | 2020 | 94 | 0.630 |
Why?
| | Vitamin D | 9 | 2024 | 397 | 0.630 |
Why?
| | Glucose | 9 | 2024 | 1020 | 0.630 |
Why?
| | Adipokines | 2 | 2010 | 49 | 0.620 |
Why?
| | Hypoxia | 2 | 2016 | 1112 | 0.590 |
Why?
| | Diabetes Mellitus | 6 | 2020 | 1040 | 0.590 |
Why?
| | Subcutaneous Fat | 5 | 2014 | 81 | 0.580 |
Why?
| | Adipocytes | 11 | 2014 | 222 | 0.560 |
Why?
| | Humans | 87 | 2025 | 137585 | 0.530 |
Why?
| | Dietary Supplements | 7 | 2022 | 561 | 0.510 |
Why?
| | Hyperglycemia | 5 | 2016 | 347 | 0.510 |
Why?
| | Aged | 31 | 2025 | 23961 | 0.490 |
Why?
| | Vitamins | 6 | 2024 | 185 | 0.490 |
Why?
| | Remote Consultation | 1 | 2016 | 54 | 0.480 |
Why?
| | Sitagliptin Phosphate | 6 | 2025 | 33 | 0.470 |
Why?
| | Liraglutide | 6 | 2025 | 30 | 0.470 |
Why?
| | Fibrosis | 3 | 2023 | 552 | 0.460 |
Why?
| | Fatty Acids | 2 | 2016 | 443 | 0.460 |
Why?
| | Macrophages | 10 | 2014 | 1547 | 0.450 |
Why?
| | Female | 50 | 2025 | 73304 | 0.440 |
Why?
| | Inflammation | 12 | 2016 | 2837 | 0.440 |
Why?
| | Male | 49 | 2025 | 67762 | 0.430 |
Why?
| | Adult | 44 | 2025 | 37929 | 0.420 |
Why?
| | C-Peptide | 3 | 2024 | 163 | 0.400 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2012 | 16 | 0.390 |
Why?
| | SUMO-1 Protein | 1 | 2012 | 21 | 0.380 |
Why?
| | Walking | 3 | 2025 | 529 | 0.380 |
Why?
| | Glucagon-Like Peptide 1 | 4 | 2025 | 135 | 0.370 |
Why?
| | Double-Blind Method | 7 | 2025 | 1993 | 0.370 |
Why?
| | Glucose Intolerance | 6 | 2010 | 146 | 0.360 |
Why?
| | Patient Admission | 1 | 2012 | 197 | 0.340 |
Why?
| | Histone Deacetylases | 1 | 2012 | 215 | 0.340 |
Why?
| | Cohort Studies | 7 | 2020 | 5742 | 0.330 |
Why?
| | Lipids | 2 | 2020 | 672 | 0.330 |
Why?
| | Receptors, Scavenger | 1 | 2009 | 23 | 0.320 |
Why?
| | Gene Expression Regulation | 6 | 2015 | 2607 | 0.310 |
Why?
| | Inpatients | 2 | 2013 | 500 | 0.300 |
Why?
| | Gene Expression | 7 | 2010 | 1502 | 0.280 |
Why?
| | Metabolic Diseases | 1 | 2008 | 108 | 0.270 |
Why?
| | Body Mass Index | 11 | 2021 | 2389 | 0.270 |
Why?
| | Intermittent Claudication | 2 | 2025 | 118 | 0.270 |
Why?
| | Adipose Tissue, White | 2 | 2019 | 41 | 0.260 |
Why?
| | Choristoma | 1 | 2007 | 21 | 0.260 |
Why?
| | Dietary Fats | 1 | 2008 | 304 | 0.250 |
Why?
| | Muscles | 3 | 2012 | 326 | 0.250 |
Why?
| | Incretins | 1 | 2025 | 22 | 0.230 |
Why?
| | Treatment Outcome | 10 | 2025 | 10811 | 0.230 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2013 | 283 | 0.220 |
Why?
| | Young Adult | 11 | 2016 | 13209 | 0.210 |
Why?
| | RNA, Messenger | 11 | 2015 | 2833 | 0.200 |
Why?
| | Adiponectin | 4 | 2009 | 244 | 0.200 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 2 | 2022 | 47 | 0.190 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1114 | 0.190 |
Why?
| | Islets of Langerhans | 2 | 2005 | 803 | 0.190 |
Why?
| | Insulin, Long-Acting | 2 | 2012 | 63 | 0.180 |
Why?
| | Ligands | 3 | 2012 | 664 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5131 | 0.170 |
Why?
| | Metoclopramide | 1 | 2020 | 19 | 0.170 |
Why?
| | Gastric Emptying | 1 | 2020 | 38 | 0.170 |
Why?
| | Glucosides | 1 | 2020 | 44 | 0.170 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5472 | 0.160 |
Why?
| | Quantitative Trait Loci | 2 | 2012 | 380 | 0.160 |
Why?
| | China | 1 | 2020 | 217 | 0.160 |
Why?
| | Benzhydryl Compounds | 1 | 2020 | 73 | 0.160 |
Why?
| | Enteral Nutrition | 2 | 2012 | 202 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2023 | 279 | 0.160 |
Why?
| | Cardiology | 1 | 2022 | 274 | 0.160 |
Why?
| | Atherosclerosis | 2 | 2018 | 415 | 0.160 |
Why?
| | Renal Insufficiency | 1 | 2021 | 162 | 0.150 |
Why?
| | Coculture Techniques | 5 | 2011 | 239 | 0.150 |
Why?
| | Insulin, Short-Acting | 1 | 2018 | 6 | 0.150 |
Why?
| | Linagliptin | 1 | 2018 | 5 | 0.150 |
Why?
| | Quality of Life | 4 | 2025 | 2892 | 0.150 |
Why?
| | Adipose Tissue, Brown | 1 | 2019 | 53 | 0.150 |
Why?
| | Cardiovascular Diseases | 3 | 2022 | 2111 | 0.150 |
Why?
| | Gene Expression Profiling | 4 | 2015 | 1774 | 0.140 |
Why?
| | Hyperoxia | 1 | 2019 | 90 | 0.140 |
Why?
| | Comparative Effectiveness Research | 3 | 2025 | 152 | 0.140 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 746 | 0.140 |
Why?
| | Incidence | 2 | 2022 | 2804 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2016 | 4193 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 558 | 0.130 |
Why?
| | Stress, Psychological | 1 | 2025 | 1100 | 0.130 |
Why?
| | Perioperative Care | 1 | 2018 | 178 | 0.130 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 259 | 0.120 |
Why?
| | Abdominal Fat | 2 | 2006 | 41 | 0.120 |
Why?
| | Endoplasmic Reticulum | 2 | 2008 | 265 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 83 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 985 | 0.120 |
Why?
| | Endocrinology | 1 | 2016 | 79 | 0.120 |
Why?
| | Arginine | 2 | 2007 | 271 | 0.120 |
Why?
| | Drug Therapy, Combination | 3 | 2024 | 1066 | 0.120 |
Why?
| | Thermogenesis | 1 | 2014 | 44 | 0.110 |
Why?
| | Cell Line | 6 | 2010 | 2847 | 0.110 |
Why?
| | Scavenger Receptors, Class E | 2 | 2015 | 2 | 0.110 |
Why?
| | Fish Oils | 1 | 2014 | 26 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1060 | 0.110 |
Why?
| | Area Under Curve | 1 | 2015 | 314 | 0.110 |
Why?
| | Hospitalization | 4 | 2018 | 2199 | 0.110 |
Why?
| | Palmitic Acid | 3 | 2011 | 41 | 0.110 |
Why?
| | Adolescent | 7 | 2016 | 21513 | 0.110 |
Why?
| | Risk Factors | 7 | 2025 | 10388 | 0.110 |
Why?
| | Adiposity | 2 | 2010 | 518 | 0.100 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2013 | 33 | 0.100 |
Why?
| | Medically Uninsured | 1 | 2014 | 130 | 0.100 |
Why?
| | ROC Curve | 1 | 2015 | 554 | 0.100 |
Why?
| | Biopsy | 3 | 2012 | 1129 | 0.100 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2011 | 218 | 0.100 |
Why?
| | Transcriptional Activation | 1 | 2014 | 378 | 0.100 |
Why?
| | Cardiomyopathies | 2 | 2007 | 350 | 0.100 |
Why?
| | PPAR alpha | 1 | 2012 | 58 | 0.100 |
Why?
| | RNA, Small Interfering | 2 | 2012 | 622 | 0.100 |
Why?
| | CD36 Antigens | 2 | 2009 | 36 | 0.100 |
Why?
| | Biphasic Insulins | 1 | 2011 | 3 | 0.090 |
Why?
| | Patient Preference | 1 | 2014 | 191 | 0.090 |
Why?
| | Seasons | 1 | 2014 | 547 | 0.090 |
Why?
| | Cytokines | 4 | 2010 | 2085 | 0.090 |
Why?
| | Insulin Lispro | 1 | 2011 | 39 | 0.090 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 3 | 2007 | 61 | 0.090 |
Why?
| | Hypolipidemic Agents | 2 | 2018 | 91 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1477 | 0.090 |
Why?
| | Temperature | 1 | 2014 | 679 | 0.090 |
Why?
| | Insulin Infusion Systems | 2 | 2012 | 394 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 284 | 0.090 |
Why?
| | Retrospective Studies | 5 | 2016 | 15657 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 631 | 0.090 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2011 | 164 | 0.090 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 84 | 0.090 |
Why?
| | Molecular Weight | 2 | 2008 | 335 | 0.090 |
Why?
| | Collagen Type VI | 1 | 2010 | 6 | 0.090 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 15 | 0.080 |
Why?
| | Lipase | 1 | 2010 | 69 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2189 | 0.080 |
Why?
| | Adipogenesis | 1 | 2010 | 55 | 0.080 |
Why?
| | Lipogenesis | 1 | 2010 | 61 | 0.080 |
Why?
| | Body Composition | 3 | 2011 | 684 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4030 | 0.080 |
Why?
| | Bicycling | 1 | 2010 | 114 | 0.080 |
Why?
| | Scavenger Receptors, Class A | 1 | 2009 | 12 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 157 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 976 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2010 | 132 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 435 | 0.080 |
Why?
| | Logistic Models | 1 | 2015 | 2074 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2031 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 294 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4295 | 0.080 |
Why?
| | Myoblasts, Skeletal | 1 | 2009 | 12 | 0.080 |
Why?
| | MicroRNAs | 1 | 2015 | 692 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2236 | 0.070 |
Why?
| | Myositis | 1 | 2009 | 52 | 0.070 |
Why?
| | Antigens, CD | 3 | 2007 | 521 | 0.070 |
Why?
| | Chemokine CCL2 | 2 | 2007 | 115 | 0.070 |
Why?
| | Biomarkers | 4 | 2025 | 4149 | 0.070 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2009 | 159 | 0.070 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2008 | 65 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2057 | 0.070 |
Why?
| | Stress, Physiological | 2 | 2008 | 443 | 0.070 |
Why?
| | Thrombospondin 1 | 1 | 2007 | 27 | 0.070 |
Why?
| | Infant | 2 | 2020 | 9465 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 1 | 2011 | 496 | 0.070 |
Why?
| | Retinol-Binding Proteins | 1 | 2007 | 18 | 0.070 |
Why?
| | TCF Transcription Factors | 1 | 2007 | 17 | 0.070 |
Why?
| | Extracellular Matrix | 1 | 2011 | 528 | 0.070 |
Why?
| | Administration, Oral | 2 | 2020 | 816 | 0.070 |
Why?
| | Adipocytes, White | 2 | 2019 | 19 | 0.070 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 17 | 0.070 |
Why?
| | Down-Regulation | 1 | 2009 | 657 | 0.070 |
Why?
| | Diacylglycerol O-Acyltransferase | 1 | 2006 | 5 | 0.070 |
Why?
| | Fatty Acid Synthases | 1 | 2006 | 24 | 0.060 |
Why?
| | Animals | 10 | 2019 | 36940 | 0.060 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 59 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 971 | 0.060 |
Why?
| | Liver | 3 | 2013 | 1943 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2011 | 1991 | 0.060 |
Why?
| | Child, Preschool | 1 | 2020 | 11074 | 0.060 |
Why?
| | Resistin | 1 | 2005 | 11 | 0.060 |
Why?
| | Niacin | 1 | 2005 | 17 | 0.060 |
Why?
| | Genome-Wide Association Study | 1 | 2012 | 1431 | 0.060 |
Why?
| | Quality Improvement | 1 | 2014 | 1178 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2025 | 37 | 0.060 |
Why?
| | Fructosamine | 1 | 2004 | 15 | 0.060 |
Why?
| | Veterans | 1 | 2016 | 1476 | 0.060 |
Why?
| | Walk Test | 1 | 2025 | 76 | 0.060 |
Why?
| | Apolipoproteins E | 1 | 2004 | 83 | 0.050 |
Why?
| | Models, Biological | 2 | 2008 | 1783 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2005 | 332 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2024 | 43 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2426 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2006 | 227 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 660 | 0.050 |
Why?
| | Leptin | 1 | 2005 | 236 | 0.050 |
Why?
| | Phenotype | 1 | 2012 | 3196 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 455 | 0.050 |
Why?
| | Elastin | 2 | 2014 | 78 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3715 | 0.050 |
Why?
| | Anti-Obesity Agents | 2 | 2018 | 57 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2025 | 279 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2006 | 264 | 0.050 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 82 | 0.050 |
Why?
| | Diabetic Ketoacidosis | 1 | 2004 | 201 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2002 | 88 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2006 | 712 | 0.050 |
Why?
| | Apoptosis | 2 | 2011 | 2553 | 0.050 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 92 | 0.040 |
Why?
| | Hypoglycemia | 2 | 2018 | 445 | 0.040 |
Why?
| | American Heart Association | 1 | 2022 | 306 | 0.040 |
Why?
| | Recovery of Function | 1 | 2025 | 653 | 0.040 |
Why?
| | Child | 1 | 2020 | 21935 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 316 | 0.040 |
Why?
| | Albuminuria | 1 | 2021 | 185 | 0.040 |
Why?
| | Coronary Artery Disease | 1 | 2007 | 698 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 201 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 310 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 220 | 0.040 |
Why?
| | Calibration | 1 | 2020 | 146 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2020 | 199 | 0.040 |
Why?
| | Creatinine | 1 | 2021 | 499 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2071 | 0.040 |
Why?
| | Adipocytes, Brown | 1 | 2019 | 7 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1242 | 0.040 |
Why?
| | Streptozocin | 1 | 2019 | 21 | 0.040 |
Why?
| | Health Status Indicators | 1 | 2020 | 171 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 683 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2006 | 1317 | 0.040 |
Why?
| | Carbohydrate Metabolism | 1 | 2019 | 59 | 0.040 |
Why?
| | Mice | 7 | 2013 | 17787 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2018 | 63 | 0.040 |
Why?
| | Transcription Factors | 2 | 2008 | 1719 | 0.040 |
Why?
| | Treatment Failure | 1 | 2019 | 356 | 0.040 |
Why?
| | Fasting | 1 | 2020 | 281 | 0.040 |
Why?
| | Digestive System Surgical Procedures | 1 | 2018 | 106 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2019 | 455 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 247 | 0.030 |
Why?
| | Urologic Surgical Procedures | 1 | 2018 | 120 | 0.030 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 195 | 0.030 |
Why?
| | Transfection | 2 | 2010 | 945 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 889 | 0.030 |
Why?
| | Blotting, Western | 2 | 2010 | 1226 | 0.030 |
Why?
| | Reference Values | 2 | 2008 | 816 | 0.030 |
Why?
| | G(M2) Activator Protein | 1 | 2015 | 1 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2018 | 216 | 0.030 |
Why?
| | Myosin Type V | 1 | 2015 | 9 | 0.030 |
Why?
| | Depression | 1 | 2025 | 1397 | 0.030 |
Why?
| | ADAM Proteins | 1 | 2015 | 61 | 0.030 |
Why?
| | 3T3 Cells | 2 | 2006 | 163 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2018 | 7635 | 0.030 |
Why?
| | Uncoupling Protein 1 | 1 | 2014 | 16 | 0.030 |
Why?
| | Fibroblasts | 2 | 2011 | 996 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 192 | 0.030 |
Why?
| | Weight Loss | 1 | 2020 | 787 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2015 | 499 | 0.030 |
Why?
| | Ion Channels | 1 | 2014 | 133 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 6828 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 494 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2013 | 3015 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 767 | 0.030 |
Why?
| | Genome, Human | 1 | 2015 | 425 | 0.030 |
Why?
| | Mast Cells | 1 | 2014 | 147 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 257 | 0.020 |
Why?
| | Demography | 1 | 2013 | 291 | 0.020 |
Why?
| | Hypertension | 1 | 2021 | 1295 | 0.020 |
Why?
| | Organ Specificity | 1 | 2012 | 305 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 596 | 0.020 |
Why?
| | TWEAK Receptor | 1 | 2011 | 5 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 843 | 0.020 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 52 | 0.020 |
Why?
| | Tripartite Motif Proteins | 1 | 2011 | 41 | 0.020 |
Why?
| | United States | 2 | 2022 | 14841 | 0.020 |
Why?
| | 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2010 | 3 | 0.020 |
Why?
| | Capillaries | 1 | 2011 | 108 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 377 | 0.020 |
Why?
| | Atrophy | 1 | 2011 | 184 | 0.020 |
Why?
| | Receptors, Adiponectin | 1 | 2010 | 19 | 0.020 |
Why?
| | Protein Kinase C-alpha | 1 | 2010 | 37 | 0.020 |
Why?
| | Rats | 1 | 2019 | 5647 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2011 | 175 | 0.020 |
Why?
| | Muscle Proteins | 1 | 2011 | 231 | 0.020 |
Why?
| | Stromal Cells | 1 | 2010 | 112 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 390 | 0.020 |
Why?
| | Th1 Cells | 1 | 2010 | 143 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2010 | 148 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 452 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2008 | 39 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2014 | 922 | 0.020 |
Why?
| | Regulatory Factor X Transcription Factors | 1 | 2008 | 11 | 0.020 |
Why?
| | X-Box Binding Protein 1 | 1 | 2008 | 10 | 0.020 |
Why?
| | Centrifugation, Density Gradient | 1 | 2008 | 41 | 0.020 |
Why?
| | Mice, Obese | 1 | 2008 | 66 | 0.020 |
Why?
| | Activating Transcription Factor 6 | 1 | 2008 | 20 | 0.020 |
Why?
| | Pilot Projects | 1 | 2014 | 1710 | 0.020 |
Why?
| | Transcription Factor CHOP | 1 | 2008 | 31 | 0.020 |
Why?
| | eIF-2 Kinase | 1 | 2008 | 31 | 0.020 |
Why?
| | Patient Readmission | 1 | 2014 | 697 | 0.020 |
Why?
| | Chelating Agents | 1 | 2008 | 75 | 0.020 |
Why?
| | Sucrose | 1 | 2008 | 110 | 0.020 |
Why?
| | Endoribonucleases | 1 | 2008 | 81 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2007 | 6 | 0.020 |
Why?
| | Cell Fractionation | 1 | 2007 | 56 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2010 | 696 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2008 | 143 | 0.020 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2007 | 26 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2007 | 40 | 0.020 |
Why?
| | Patient Discharge | 1 | 2014 | 897 | 0.020 |
Why?
| | Cell Communication | 1 | 2009 | 315 | 0.020 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2006 | 7 | 0.020 |
Why?
| | Phosphatidate Phosphatase | 1 | 2006 | 5 | 0.020 |
Why?
| | Indians, North American | 1 | 2013 | 643 | 0.020 |
Why?
| | Blotting, Northern | 1 | 2006 | 201 | 0.020 |
Why?
| | Signal Transduction | 2 | 2011 | 5079 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2008 | 404 | 0.020 |
Why?
| | Muscle Cells | 1 | 2006 | 43 | 0.020 |
Why?
| | Isomerism | 1 | 2006 | 56 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2008 | 195 | 0.020 |
Why?
| | Caspase 9 | 1 | 2006 | 57 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.020 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2006 | 37 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2008 | 338 | 0.020 |
Why?
| | Anilides | 1 | 2006 | 73 | 0.020 |
Why?
| | DNA Primers | 1 | 2006 | 515 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2006 | 5757 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2844 | 0.010 |
Why?
| | Caspase 3 | 1 | 2006 | 246 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 363 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 247 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 324 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1092 | 0.010 |
Why?
| | Genome | 1 | 2006 | 300 | 0.010 |
Why?
| | Life Style | 1 | 2006 | 490 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2004 | 269 | 0.010 |
Why?
| | Colorado | 1 | 2014 | 4565 | 0.010 |
Why?
| | Homeostasis | 1 | 2007 | 621 | 0.010 |
Why?
| | RNA | 1 | 2010 | 921 | 0.010 |
Why?
| | Stem Cells | 1 | 2007 | 594 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2004 | 190 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2181 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 622 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2006 | 706 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2139 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2900 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1199 | 0.010 |
Why?
| | Antioxidants | 1 | 2006 | 584 | 0.010 |
Why?
| | Genotype | 1 | 2007 | 1916 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2006 | 1738 | 0.010 |
Why?
| | Myocardium | 1 | 2006 | 1002 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2002 | 155 | 0.010 |
Why?
| | Morbidity | 1 | 2002 | 324 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2008 | 1502 | 0.010 |
Why?
| | Cardiovascular System | 1 | 2002 | 137 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2002 | 255 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7604 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1250 | 0.010 |
Why?
| | Mortality | 1 | 2002 | 362 | 0.010 |
Why?
| | Mitochondria | 1 | 2006 | 948 | 0.010 |
Why?
|
|
Rasouli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|